NASDAQ:OVID Ovid Therapeutics Q1 2025 Earnings Results & Report $2.28 +0.10 (+4.34%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Ovid Therapeutics met analyst earnings expectations and beat on revenue in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.14 versus the -$0.14 consensus estimate, while revenue of $0.13 million topped the $0.03 million estimate by $0.10 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call3:00 AM ET Ovid Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.14Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersOvid Therapeutics Revenue ResultsActual Revenue$0.13 millionExpected Revenue$0.03 millionBeat/MissBeat by +$97.00 thousandYoY Revenue GrowthN/AUpcoming EarningsOvid Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Ovid Therapeutics Q1 2025 Earnings FAQ Did Ovid Therapeutics beat earnings estimates for Q1 2025? Ovid Therapeutics (NASDAQ:OVID) reported earnings of -$0.14 per share for Q1 2025, matching the consensus estimate of -$0.14. The report was announced on Tuesday, May 13, 2025. What was Ovid Therapeutics' revenue for Q1 2025? Ovid Therapeutics reported revenue of $0.13 million for Q1 2025, against a consensus estimate of $0.03 million. When is Ovid Therapeutics' next earnings date? Ovid Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ovid Therapeutics on the company's earnings history page. Ovid Therapeutics Earnings HeadlinesOvid Therapeutics (NASDAQ:OVID) Stock Rated "Moderate Buy" by Wall Street AnalystsOctober 12 at 2:44 AM | americanbankingnews.comCantor Fitzgerald initiates coverage of Ovid Therapeutics with overweight ratingOctober 9, 2026 | msn.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)Ovid Therapeutics (OVID) Stock Gets Fair Value Boost As Analysts Focus On OV329October 8, 2026 | finance.yahoo.comOvid Therapeutics (NASDAQ:OVID) Upgraded at GuggenheimOctober 7, 2026 | americanbankingnews.comGuggenheim Initiates Ovid Therapeutics at BuyOctober 7, 2026 | marketscreener.comMSee More Ovid Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ovid Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ovid Therapeutics and other key companies, straight to your email. Email Address About Ovid TherapeuticsOvid Therapeutics (NASDAQ:OVID) Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for rare neurological disorders, including epilepsies and neurodevelopmental conditions. The company’s research programs are designed to address diseases with significant unmet medical needs and limited treatment options. Ovid has developed a pipeline of investigational therapies targeting the underlying biology of neurological disorders. Its programs have included treatments for seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, as well as potential therapies for other rare epileptic and neurodevelopmental conditions. The company does not have a broad portfolio of approved commercial products. Founded in 2014, Ovid has advanced its programs through collaborations with pharmaceutical companies, including a development partnership with Takeda Pharmaceutical Company involving soticlestat. Its clinical development activities have involved patients and research sites in the United States and other international markets. Ovid is headquartered in New York.View Ovid Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth PathIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
